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Abstract
Initial studies of 88 transmission pairs in the Zambia Emory HIV Research Project cohort demonstrated that the number of
transmitted HLA-B associated polymorphisms in Gag, but not Nef, was negatively correlated to set point viral load (VL) in
the newly infected partners. These results suggested that accumulation of CTL escape mutations in Gag might attenuate
viral replication and provide a clinical benefit during early stages of infection. Using a novel approach, we have cloned gag
sequences isolated from the earliest seroconversion plasma sample from the acutely infected recipient of 149
epidemiologically linked Zambian transmission pairs into a primary isolate, subtype C proviral vector, MJ4. We determined
the replicative capacity (RC) of these Gag-MJ4 chimeras by infecting the GXR25 cell line and quantifying virion production in
supernatants via a radiolabeled reverse transcriptase assay. We observed a statistically significant positive correlation
between RC conferred by the transmitted Gag sequence and set point VL in newly infected individuals (p = 0.02).
Furthermore, the RC of Gag-MJ4 chimeras also correlated with the VL of chronically infected donors near the estimated date
of infection (p = 0.01), demonstrating that virus replication contributes to VL in both acute and chronic infection. These
studies also allowed for the elucidation of novel sites in Gag associated with changes in RC, where rare mutations had the
greatest effect on fitness. Although we observed both advantageous and deleterious rare mutations, the latter could point
to vulnerable targets in the HIV-1 genome. Importantly, RC correlated significantly (p = 0.029) with the rate of CD4+ T cell
decline over the first 3 years of infection in a manner that is partially independent of VL, suggesting that the replication
capacity of HIV-1 during the earliest stages of infection is a determinant of pathogenesis beyond what might be expected
based on set point VL alone.
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Introduction
Despite a diverse HIV-1 quasispecies within chronically infected
individuals, a single variant establishes infection in the majority of
heterosexual transmission cases, resulting in a severe genetic
bottleneck [1–3]. A more profound understanding of the
interaction between host and viral characteristics and how they
shape early pathogenesis and disease progression will be integral
for understanding the trajectory and impact of early events after
heterosexual transmission. While it is well established that host
factors such as HLA-class I alleles can play a major role in
determining clinical progression in those individuals recently
infected with HIV-1 [4–10] the role of transmitted viral
characteristics has been understudied due to the lack of suitable
cohorts in which virus from both the donor and linked recipient
are available. Accordingly, studies using epidemiologically linked
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heterosexual transmission pairs are essential for understanding
how viral evolution, adaptation, and the characteristics of the
transmitted variant influence HIV-1 pathogenesis.
Previous studies in both heterosexual and homosexual trans-
mission pairs have demonstrated that viral loads (VL) in the newly
infected partners are correlated with VL in the transmitting
partner [11–13]. This finding is intriguing as the majority of the
linked couples have disparate HLA-I alleles, and would therefore
have varying immune responses to the incoming virus. Thus, the
characteristics of the virus in the donor quasispecies that impact
replication can similarly impact the replication of the newly
infecting virus even in the context of what is frequently a distinct
immunogenetic environment. Indeed, when host factors known to
modulate VL such as the presence of protective or unfavorable
HLA-I alleles, gender, age, and HLA-B sharing are taken into
account in a multivariable analysis utilizing a general linearized
model, the correlation between donor and recipient VL becomes
highly significant (Yue et al., manuscript in submission).
It is clear that both humoral [14] and cellular immune responses
can drive virus evolution over the course of infection. In the case of
the latter, escape mutations arise that abrogate the ability of
cytotoxic T lymphocytes (CTL) to kill virus-infected cells [15–22].
While the selection of CTL escape mutations provides an in vivo
advantage for the virus, if a mutation occurs within a functionally
constrained region of the genome such as Gag, it could reduce in
vitro replicative fitness [17,23–30]. This phenomenon has been
demonstrated for several CTL escape mutations associated with
protective alleles such as HLA-B*57, B*5801, B*27, and B*81
[31–36]. The ability of protective alleles to target conserved
regions of the genome that escape with difficulty, due to the fitness
costs incurred by mutations at these epitopes, may partially explain
the mechanism of enhanced protection from disease progression in
individuals with these alleles [37–41]. While evasion from the CTL
response may result in such deleterious mutations, the in vivo fitness
benefit outweighs that of the replication cost [42], and the ongoing
selection of additional mutations may allow the virus to
compensate for these defects [17,29,32,33,35,43–49]. The func-
tional consequence of escape and compensatory mutations upon
transmission to an HLA-mismatched individual has not been fully
explored.
Initial studies in the ZEHRP cohort of 88 transmission pairs
demonstrated that the number of transmitted HLA-B associated
polymorphisms in Gag, but not Nef, was negatively correlated to
set point VL in the newly infected partners, suggesting that an
accumulation of escape mutations might attenuate viral replication
and provide a clinical benefit during early stages of infection [50].
In addition, in a smaller study of nine newly infected individuals
infected by viruses with fitness reducing HLA-B*5703 associated
epitope-escape mutations in p24, a lower set point VL was
observed [24]. Previous studies have also shown that elite
controllers can harbor viruses with gag-pro sequences that confer
reduced in vitro replicative capacities (RC) [51–53]. In a series of
studies, Brockman and colleagues have shown that in vitro RC
conferred by gag-pro variants isolated from both subtype B and C
chronically infected individuals correlates to VL, demonstrating
the role of intrinsic viral characteristics in defining this marker of
pathogenesis [43,47,54,55]. However, in these studies the recom-
bination of population-based PCR amplified sequences into the
lab adapted NL4.3 provirus required the outgrowth of virus in a
CEM-CCR5 based cell line, potentially skewing the nature of the
virus recovered. In contrast, studies of HIV-1 fitness in acute
infection did not yield a statistically significant correlation between
RC and VL, potentially due to small sample sizes and the
limitations of the methodologies used.
The identification of 149 heterosexual epidemiologically linked
transmission pairs from a discordant couple cohort in Lusaka,
Zambia, provides a unique opportunity to investigate the role that
HLA-mediated adaptation of Gag within a chronically infected
individual plays in modulating the RC of the transmitted variant.
We hypothesize that HLA-mediated adaptation of HIV-1 resulting
in Gag variants conferring varying levels of RCs will be a major
viral characteristic linking donor and recipient VLs, and that the in
vitro RC conferred by the transmitted Gag sequence defines early
clinical parameters of HIV-1 pathogenesis.
To test this hypothesis and using a novel approach, we cloned
gag sequences from the earliest seroconversion plasma sample from
149 newly infected recipients of epidemiologically linked Zambian
transmission pairs into the MJ4 proviral backbone [56]. The RC
of each Gag-MJ4 chimera was then determined and used to
investigate how the RC conferred by the transmitted Gag
sequence defines clinical parameters, such as early set point VL
and CD4+ T cell decline in the newly infected individuals. These
studies allowed us to identify novel residues in Gag that influence
RC, and demonstrate a strong correlation between RC and early
set point VL, as well as between RC and CD4 decline during the
first three years of infection, which was also found to be
independent of VL. Thus, the RC of the transmitted virus as




All participants in the Zambia Emory HIV Research Project
(ZEHRP) discordant couples cohort in Lusaka, Zambia were
enrolled in human subjects protocols approved by both the
University of Zambia Research Ethics Committee and the Emory
University Institutional Review Board. Prior to enrollment,
individuals received counseling and signed a written informed
consent form agreeing to participate. The subjects selected from
the cohort were initially HIV-1 serodiscordant partners in
cohabiting heterosexual couples with subsequent intracouple
Author Summary
In the majority of HIV-1 cases, a single virus establishes
infection. However, mutations in the viral genome accu-
mulate over time in order to avoid recognition by the host
immune response. Certain mutations in the main structural
protein, Gag, driven by cytotoxic T lymphocytes are
detrimental to viral replication, and we showed previously
that, upon transmission, viruses with higher numbers of
escape mutations in Gag were associated with lower early
set point viral loads. We hypothesized that this could be
attributed to attenuation of the transmitted virus. Here, we
have cloned the gag gene from 149 newly infected
individuals from linked transmission pairs into a clade C
proviral vector and determined the replicative capacity in
vitro. We found that the replicative capacity conferred by
the transmitted Gag correlated with set point viral loads in
newly infected individuals, as well as with the viral load of
the transmitting partner, and we identified previously
unrecognized residues associated with increasing and
decreasing replicative capacity. Importantly, we demon-
strate that transmitted viruses with high replicative
capacity cause more rapid CD4+ decline over the first
three years, independent of viral load. This suggests that
the trajectory of pathogenesis may be affected very early
in infection, before adaptive immunity can respond.
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(epidemiologically linked) HIV-1 transmission [57–59]. Epidemi-
ological linkage was defined by phylogenetic analyses of HIV-1
gp41 sequences from both partners [60]. Viral isolates from each
partner in the transmission pair were closely related, with median
and maximum nucleotide substitution rates of 1.5 and 4.0%,
respectively. In contrast, median nucleotide substitution rate for
unlinked HIV-1 C viruses from the Zambian cohort and elsewhere
was 8.8% [60]. The algorithm used to determine the estimated
date of infection (EDI) was previously described by Haaland et al.
[2]. All patients in this cohort were antiretroviral therapy naı¨ve.
Zambian linked recipients were identified 45.5 days (median,
IQR = 41.5–50.5) after the estimated date of infection, at which
time plasma samples were obtained from both the transmitting
partner (donor) and the seroconvertor (recipient). The vast
majority (95%) of HIV-1 sequences derived from ZEHRP
transmission pairs belonged to HIV-1 subtype C with subtypes
A, D, G, and J being detected only occasionally [60]. All of the
transmission pairs utilized in this study are infected with subtype C
HIV-1.
Viral loads and CD4+ count measurements
Early set point VL for newly infected individuals was defined as
the earliest stable nadir VL value measured between 3 and 9
months post infection and which did not show a significant
increase in value within a 3–4 month window. HIV plasma VL
was determined at the Emory Center for AIDS Research Virology
Core Laboratory using the Amplicor HIV-1 Monitor Test (version
1.5; Roche). CD4+ T cell counts were based on T-cell
immunophenotyping, with assays done using the FACScount
System (Beckman Coulter Ltd., London, United Kingdom) in
collaboration with the International AIDS Vaccine Initiative.
HLA-class I genotyping
Genomic DNA was extracted from whole blood or buffy coats
(QIAamp blood kit; Qiagen). HLA class I genotyping relied on a
combination of PCR-based techniques, involving sequence-specif-
ic primers (Invitrogen) and sequence-specific oligonucleotide
probes (Innogenetics), as described previously [10]. Ambiguities
were resolved by direct sequencing of three exons in each gene,
using kits (Abbott Molecular, Inc.) designed for capillary electro-
phoresis and the ABI 3130xl DNA Analyzer (Applied Biosystems).
Amplification and sequencing of gag from donors and
linked recipients
Viral RNA was extracted from 140 mL plasma samples using
the Qiagen viral RNA extraction kit (Qiagen). Gag-pol population
sequences were generated using nested gene specific primers.
Combined RT-PCR and first round synthesis was performed using
SuperScript III Platinum One Step RT-PCR (Invitrogen) and
5 mL viral RNA template. RT-PCR and first round primers
include GOF (forward) 59 ATTTGACTAGCGGAGGCTAGAA
39 and VifOR (RT-PCR and reverse) 59 TTCTACGGAGACTC-
CATGACCC 39. Second round PCR was performed using
Expand High Fidelity Enzyme (Roche) and 1 mL of the first
round PCR product. Nested second round primers include GIF
(forward) 59 TTTGACTAGCGGAGGCTAGAAGGA 39 and
VifIR (reverse) 59 TCCTCTAATGGGATGTGTACTTCT-
GAAC 39. Three positive amplicons per individual were pooled
and purified via the Qiagen PCR purification kit (Qiagen).
Purified products were sequenced by the University of Alabama at
Birmingham DNA Sequencing Core. Sequence chromatograms
were analyzed using Sequencher 5.0 (Gene Codes Corp.), and
degenerate bases were denoted using the International Union of
Pure and Applied Chemistry codes when minor peaks exceeded at
least thirty percent of the major peak height.
The percent similarity between donor and recipient population gag
sequences was determined by building a neighbor-joining tree using
Geneious v5.5.7 (Biomatters Ltd.). The percent similarity between
nucleotide and amino acid alignment was determined based on the
output matrix from these neighbor-joining trees. In calculating the
percent similarity between amino acid sequences, degenerate bases
that resulted in non-synonymous changes and, thus, a mixture of
amino acid residues, were translated as an ‘‘X’’. When one of the
amino acids comprising a mixture in the donor was found in the
recipient Gag sequence, this was counted as a mismatch, making the
average percent similarity reported between donor and recipient gag
sequences a maximal estimate of percent mismatch.
Generation of Gag-MJ4 chimeras
Viral RNA was extracted from linked recipients at the day of
seroconversion time point using the Qiagen viral RNA extraction
kit (Qiagen). First round PCR products were generated as was
previously described for the gag sequencing of all 149 transmission
pairs [50]. Second round PCR was performed to generate gag
amplicons for Gag-MJ4 chimera generation using Phusion Hot
Start II polymerase (Fisher) and 1 mL of the first round PCR
product. Nested second round primers include GagInnerF1
(forward) 59 AGGCTAGAAGGAGAGAGATG 39 and BclIDe-
gRev2 (reverse) 59 AGTATTTGATCATAYTGYYTYACTTTR
39, which generate a gag amplicon starting from the initiation
codon of gag and extending 142 nucleotides after the gag stop
codon and into pro. The 59 portion of the MJ4 long terminal repeat
(LTR) was amplified using Phusion Hot Start II polymerase and
the MJ4For1b (forward) 59 CGAAATCGGCAAAATCCC 39 and
MJ4Rev (reverse) 59 CCCATCTCTCTCCTTCTAGC 39 primer
set. In order to make the proper insert for cloning, the patient-
specific gag and MJ4-LTR sequences were joined using a splice-
overlap extension PCR utilizing the MJ4For1b (forward) and
BclIRev (reverse) 59 TCTATAAGTATTTGATCATACT-
GTCTT 39 primer set. Joined splice-overlap-extension PCR
products were gel purified using the Qiagen gel extraction kit
(Qiagen). Purified Gag-LTR inserts and wild-type MJ4 vector (NIH
AIDS Research and Reference Reagent Program, [56]) were digested
with NgoMIV and BclI restriction enzymes (NEB) and ligated
overnight at 4uC with T4 DNA ligase (Roche) at a 3:1 insert to vector
ratio. JM109 competent cells were transformed with ligation products,
plated onto LB/agar plates supplemented with 100 mg/ml ampicillin
and grown at 30uC. Gag-MJ4 chimeric DNA was isolated from
cultures using the Qiagen miniprep kit (Qiagen). Gag-MJ4 chimeras
were sequenced to confirm gag insert fidelity as compared to previously
amplified population sequences. Two identical independent clones per
linked recipient were chosen for replication assays in order to ensure
backbone fidelity during the cloning process.
Generation and titration of viral stocks
Viral stocks were generated by transfecting 1.5 mg purified
proviral plasmid DNA into 293T cells (American Type Culture
Collection) using the Fugene HD transfection reagent (Roche)
according the manufacturer’s protocol. Viral stocks were collected
72 hrs post transfection, clarified by low-speed centrifugation, and
frozen at 280uC. The titer of each viral stock was determined by
infecting TZM-bl cells (NIH AIDS Research and Reference
Reagent Program) with 5-fold serial dilutions of virus in a manner
previously described [36,61].
Both 293T and TZM-bl cell lines were maintained in complete
Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supple-
mented with 10% fetal bovine serum (HyClone Laboratories),
HIV-1 Replicative Capacity and Early Pathogenesis
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2 mM L-glutamine, and 100 U/ml penicillin G sodium, and
100 mg/ml streptomycin sulfate (Gibco) at 37uC and 5% CO2.
In vitro replication capacity (RC) assay
In order to assess the RC of Gag-MJ4 chimeras, 56105 GXR25
cells [62] were infected at an MOI of 0.05, and 100 ml of viral
supernatants were collected at 2 day intervals. Briefly, GXR25
cells and virus were incubated with 5 mg/ml polybrene at 37uC for
3 hours, washed 5 times with complete Roswell Park Memorial
Institute (RPMI) medium (Gibco) and plated into 24-well plates.
Cells were split 1:2 to maintain confluency, replaced with an equal
volume of fresh media, and viral supernatants were taken at days
2, 4, 6, and 8 as previously described [36,61]. Virion production
was quantified using a 33P-labeled reverse transcriptase assay.
Based on values obtained for days 2–8, the optimal window for
logarithmic growth for all viruses was determined to be between
days 2 and 6, as by day 8 many high replicating viruses had
exhausted target cells causing a flattening or decline of the
replication curve. Therefore, log10-transformed slopes were
calculated based on days 2, 4, and 6 for all viruses. Replication
scores were generated by dividing the log10-transformed slope of
the replication curve for each Gag-MJ4 chimera by the log10-
transformed slope of wild-type MJ4. Two independent Gag-MJ4
chimera clones per acutely infected linked recipient were run in
duplicate to confirm cloning fidelity. After both independent
clones were confirmed to have identical replicative capacities, one
clone was subsequently run in triplicate in two independent
experiments in order to generate consistent replicative capacity
scores. GXR25 cells were maintained in complete RPMI medium
supplemented with 10% fetal bovine serum (HyClone Laborato-
ries), 100 U/ml penicillin G sodium, 100 mg/ml streptomycin
sulfate (Gibco), and 10 mM HEPES buffer at 37uC and 5% CO2.
Quantification of HIV-1 reverse transcriptase
Aliquots of culture supernatants from infected cells were added
to an RT-PCR master mix [63] and incubated at 37uC for
2 hours; then the RT-PCR product was blotted onto DE-81
paper, and allowed to dry. Blots were washed 5 times with 16SSC
(0.15 M NaCl, 0.015 M sodium citrate, pH 7.0) and 3 times with
90% ethanol, allowed to dry, and exposed to a phosphoscreen
(Perkin Elmer) overnight. Counts were read using a Cyclone
PhosphorImager [36,61].
HIV-1 Gag polymorphism scores
HLA-associated polymorphisms were defined as any non-
consensus polymorphism that occurred at an amino acid position
having known escape mutations adapted to specific HLA-class I
alleles as defined by a list of associations generated in a manner
similar to that described previously [44,64] from 1899 subtype C
gag sequences from Zambia and South Africa (Carlson, et al.,
manuscript in preparation). Polymorphisms that increased or
decreased replicative capacity were defined based on amino acid
associations with RC derived from an exploratory pair-wise
analysis detailed in the experimental results. To generate a
summed polymorphism score, the number of HLA-associated
fitness-decreasing polymorphisms was subtracted from the number
of HLA-associated fitness-increasing polymorphisms.
Statistical analysis
The relationships between RC and set point VL, donor VL, and
average CD4+ counts; RC and the number and quality of HLA-
associated polymorphisms; and VL and the number and quality of
HLA-associated polymorphisms were analyzed using the Spear-
man rank correlation. Linear regression analyses were utilized to
generate trend lines to facilitate visualization of correlation graphs.
Mann-Whitney tests were used to compare the differences in RC
between rare and more common polymorphisms. Mann-Whitney
tests were used to analyze the difference in median set point VLs
between different RC groups (RC,1, RC = 1–2, RC.2). All
Spearman correlations, Mann-Whitney tests, and linear regression
analyses were performed using Prism GraphPad v5.0 (GraphPad
Software, Inc.).
The Mann-Whitney U test was used to identify statistically
significant differences in RC between two groups (e.g. sequences
with or without a given HIV polymorphism). Multiple tests were
addressed using q-values [65], which estimates the expected
proportion of significant tests that are false positives. To limit the
number of tests, we considered only groups containing at least 3
individuals.
A subset of volunteers with longitudinal CD4+ T cell counts
(n = 63) was analyzed to characterize the relationship between RC
and T cell decline. Survival analysis was used to estimate the
association between replicative capacity (RC) and the drop of
CD4+ cell count. The endpoint is defined as the time before CD4+
T cell counts drop below a threshold, e.g. 300 or 350 cells/mm3.
The set point VL is another factor being considered. Kaplan
Meier curve and log-rank test were used to compare the survival
between the groups with RC,1 and RC.2. Cox proportional
hazard regression was used to assess risk associated with high RC
with or without adjustment for the confounding factor of set point
VL. The sample size (n = 66) was inadequate for a more complete
analysis with additional covariates.
Results
Selection and characterization of transmitted gag
sequences
Studying heterosexual transmission of HIV-1 within the context
of discordant couples allows for full characterization of viruses
from both donor and recipient. From a total of 294 epidemiolog-
ically linked transmission pairs identified from 1998–2010 in the
Zambia Emory HIV Research Project (ZEHRP) discordant couple
cohort [66], we selected 149 individuals that had been enrolled for
at least 1 year and had at least 9 months of follow up post
serconversion. The median time post estimated date of infection
(EDI) for all 149 individuals was 45 days. Thus, this represents a
unique early infection linked transmission pair cohort.
The median log10 VL for donors near the time of transmission
and the median log10 set point VL for linked recipients was 5.02
(IQR = 4.51–5.45) and 4.39 (IQR = 3.91–4.99) respectively for all
participants included in this study. Figure S1 depicts the
phylogenetic clustering of population sequences for the gag gene
of the 149 epidemiologically linked transmission pairs and
highlights the high degree of sequence similarity between donor
and recipient viruses.
The majority of population gag sequences isolated from acute/
early time points of linked recipients were homogeneous and in
most cases were identical to the donor population gag sequence
isolated near the EDI. Overall, donor and linked recipient
sequences differed in amino acid composition by only 2.7%.
Mutations were counted when a mixture of nucleotides (amino
acids) in the donor population sequence resolved to a single
residue in the recipient and thus represent maximal values. Of the
149 pairs only 37 recipient sequences had evidence of potential
early escape and a majority of these individuals (28/37) had only a
single amino acid change. Therefore, we can conclude that the
majority of the sequence polymorphisms present at the serocon-
HIV-1 Replicative Capacity and Early Pathogenesis
PLOS Pathogens | www.plospathogens.org 4 November 2012 | Volume 8 | Issue 11 | e1003041
version time point are derived from the chronically infected donor.
Additional characteristics of the cohort including set point VL and
CD4+ counts are listed in Table 1.
Construction of Gag-MJ4 chimeric viruses
Previous studies investigating the role of Gag viral fitness have
employed a recombination approach in which sequences are PCR
amplified as a bulk population, allowed to recombine into a gag-
deleted NL4-3, and resulting viruses propagated in permissive cells
[43,47,51,53–55]. This method has three distinct disadvantages:
there is no control over the sites of recombination, it requires the
outgrowth of virus which may select for the most fit virus in the
population and could also select for sequence changes, and the
introduction of subtype C sequences into a lab adapted subtype B
proviral backbone may introduce biases due to the interaction of
subtype B proteins with subtype C Gag. In order to avoid these
limitations and because we are studying individuals recently
infected with HIV, where the population is generally homoge-
neous, we have employed a direct cloning method that allows for
the introduction of the entire gag gene into a replication
competent, CCR5 tropic, clade C provirus, MJ4 [56].
A splice-overlap-extension PCR was employed to fuse the MJ4-
LTR-U5 sequence with the transmitted gag sequence. This ensures
that the cis-acting sequences upstream of Gag, which may
influence expression levels, are constant throughout all constructs.
The resulting chimeras include the entire transmitted gag sequence
from the initiation codon to the end of Gag and extend into
conserved region of protease by 47 amino acids. For each newly
infected individual, at least two independent Gag-MJ4 chimeras
were sequence confirmed and assayed for replicative capacity
(RC). An analysis of variation of RC between the two independent
clones derived from each newly infected linked recipient was
8.5%. Testing two independent clones, therefore, ensures that the
observed RC is not due to the confounding effect of backbone
mutations that might have arisen during the cloning process and
provides an estimate of experimentally induced variation.
Overall, a low amount of heterogeneity was detected in gag
population sequences isolated from linked recipients, with only
28% having one or more mixed bases resulting in amino acid
changes in the sequences from which the Gag-MJ4 chimeras were
generated. When this was the case, the gag clone with the sequence
closest to the donor gag sequence was chosen in order to avoid
sampling gags containing de novo escape or reversion. In some cases
in which multiple variants appeared to be transmitted, several gag
variants were assayed for RC as described in the materials and
methods section. In each case, these minor variants were found to
have similar or identical RC values (data not shown).
Introduction of gag sequences from newly infected
individuals into MJ4 drastically alters replicative capacity
In initial replication assays performed in order to test assay
precision, wild-type MJ4 exhibited an intra-assay variability of
10.4% and an inter-assay variability of 8.7%. Figure 1 shows the
results of a typical experiment for all 149 Gag-MJ4 chimeras, with
wild-type MJ4 depicted in red. The normalized RC values of the
chimeras ranged from less than 0.01 to greater than 3.5. Some
viruses replicated more than 100 times more efficiently than MJ4,
demonstrating that substitution of Gag can have a profound
impact on the ability of the virus to replicate in cells.
Correlation between the replicative capacities conferred
by transmitted gag sequences and viral loads in newly
infected individuals and their transmitting partners
An examination of the RC of transmitted viruses allows us to
determine the role of viral replication in defining set point VL in
acutely infected individuals before significant viral adaptation to
immune pressure of the host has taken place, which might
confound the relationship of RC to VL. We observed a statistically
significant positive correlation between the replicative capacities of
Gag-MJ4 chimeras and set point VLs in newly infected individuals
(Figure 2A; Spearman correlation r = 0.17, p = 0.02), a correlation
that persists when conditioning on the presence of B*57 in, and the
sex of, the linked recipient (p = 0.009). This finding indicates that
the RC conferred by the transmitted Gag sequence clearly plays a
role in defining early set point VL of newly infected Zambian
linked recipients.
In several cohorts VL in the transmitting partner and that in the
linked seroconvertor have been shown to be correlated [11–13]. In
order to more fully explore the possible contribution of RC in
explaining this phenomenon, we compared VLs of the transmit-
ting partner at the time of transmission to the RC defined by the
Table 1. Cohort statistics generated from the 149
transmission pairs selected from the ZEHRP cohort.
Parameters Linked Seroconverter (SC)
Number of individuals 149
Number of Females (%) 77 (52%)
Age of SC at time of seroconversion 28 (24–35)a
Estimated days post infection 45.5 (41.5–50.5)a
Log10 Set-point VL of SC 4.39 (3.91–4.99)
a
Log10 VL of Donor Partner
b 5.02 (4.51–5.45)a
CD4 cell count 1 yr post SCc 383 (308–503)a
aMedian (Inter-Quartile Range).
bMeasured at or within one month of seroconversion of LR.
cLR for whom we have longitudinal CD4+ T cell counts (n = 63).
doi:10.1371/journal.ppat.1003041.t001
Figure 1. Insertion of the gag gene from newly infected
individuals dramatically alters the replicative capacity of
MJ4. In order to generate replication curves, 56105 GXR25 cells were
infected with Gag-MJ4 chimeras at an MOI of 0.05. Viral supernatants
(100 mL) were collected on days 2, 4, and 6, and the amount of virus in
supernatants was quantified using a radiolabeled reverse transcriptase
assay. Replicative capacity scores were generated by dividing the log10-
transformed slope of replication of each Gag-MJ4 chimera by the log10-
transformed slope of MJ4. It is clear that the insertion of the gag gene
alone can dramatically alter the in vitro RC, generating viruses with up
to 1000-fold different replication curves. DLU, digital light units.
doi:10.1371/journal.ppat.1003041.g001
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transmitted Gag sequence. Despite both a higher maximum and
wider range of VLs within transmitting partners, we observed a
statistically significant positive correlation between RC and the set
point VL of the donors, similar to that of their newly infected
partners (Figure 2B; Spearman correlation r = 0.18, p = 0.01). This
supports the concept that RC, defined by Gag, is a viral
characteristic contributing to the positive correlation between
donor and recipient VLs that has been previously reported [11–13].
Several amino acids in Gag significantly correlate to
changes in replicative capacity
Uncovering sites of vulnerability in HIV-1 is a high priority for the
informed design of an effective HIV vaccine [21]. Therefore, we
examined all 149 Gag sequences and their RC using an exploratory
pairwise analysis described previously [43,54], to uncover residues
that significantly affect the virus’ ability to replicate in vitro. We found
49 residues at 31 unique positions that had a statistically significant
effect on RC at p,0.05 (q,0.51) and 4 residues at 3 unique positions
that were significant at p,0.002 (q,0.2) (Table S1). In what follows,
we will use q,0.2 as the significance threshold when individual sites
of significance are considered, and q,0.51 (p,0.05) as the
significance threshold when we are testing broad trends, in which
we are willing to increase our expected false positive rate as a tradeoff
to substantially reduce our expected false negative rate.
The locations of all statistically significant polymorphisms
(p,0.05), along with their effects on RC as compared to the
median RC of all viruses, are plotted linearly on a graphical
representation of the Gag protein (Figure 3A.). Residues that
dramatically modulate RC were enriched in p17 and p2 (Fisher’s
exact test, p,0.0001). In addition, roughly two-thirds of the non-
consensus residues with p,0.05 increase fitness relative to the
median RC for the entire population.
An expanded data set of 1899 subtype C gag sequences from
Zambia and South Africa (Carlson, Schaefer et. al., manuscript in
preparation) was utilized to identify residues that affected RC and
were also HLA-associated. Within this data set, HLA-associated
polymorphisms are classified as being either adapted or non-
adapted. An adapted residue is one that is escaped relative to the
HLA-allele in question. In contrast, a residue that is non-adapted is
the susceptible form and may render the virus vulnerable to
immunological targeting by the HLA-allele in question. This new
dataset has identified a total of 199 HLA-linked polymorphisms
(q,0.2, p,0.0007) vs. 59 associations utilized previously from a
smaller subset of gag sequences [27,50]. Within the 49 residues
associated with changes in RC, 7 polymorphisms were found to be
adapted to specific HLA class I alleles, clearly demonstrating the
impact of the cellular immune response in affecting viral fitness
(Figure 3B, * denotes q,0.2). Six polymorphisms were found to be
non-adapted to specific HLA class I alleles (Figure 3C, * denotes
q,0.2). Since these are non-consensus polymorphisms, it is possible
that consensus at these residues is escaped relative to these HLAs,
potentially explaining why an adapted consensus residue at this
position is the less fit variant. Indeed, 5 consensus residues (62K,
451S, 488S, 85L, and 309A) with p,0.05 were found to be adapted
to HLA-I alleles, demonstrating that the cellular immune response
can drive selection for consensus residues.
Rare polymorphisms have the greatest effect on
replicative capacity
During our analysis of amino acid polymorphisms linked to
changes in RC (p,0.05), we observed a negative correlation
between the frequency of polymorphisms and the magnitude of
their effect on RC (Spearman correlation, r =20.89, p,0.0001).
Indeed, rare polymorphisms, those occurring in less than 10 of the
149 individuals studied, had significantly greater impact (both
negative and positive) on RC than polymorphisms that occurred
more frequently (Figure 4A and 4B). This finding is especially
intriguing in the case of rare deleterious mutations, as these
residues may highlight epitopes at which HIV escapes or
compensates for fitness defects with great difficulty, similar to
those described for elite controllers [52], and may, therefore, be
attractive targets for a cellular-based vaccine.
The cumulative and qualitative effect of HLA associated
polymorphisms in Gag on replicative capacity
In order to investigate whether there is a cumulative effect of
viral escape from cellular immune pressure in Gag on RC, the
Figure 2. Replicative capacity is correlated to viral load in
recipients and donors. (A) The RC of Gag-MJ4 chimeras generated
from gag sequences isolated from epidemiologically linked recipients at
acute time points correlates to early set point VL in the same acutely
infected recipients (Spearman correlation, r = 0.17, p = 0.02). Replicative
capacity scores were generated by normalizing the log10-transformed
slopes of replication curves from days 2 through 6 for each Gag-MJ4
chimeric virus to the log10-transformed slope of wild-type MJ4. (B) The
RC of Gag-MJ4 chimeric viruses also correlates to the VL near the
estimated date of infection in chronically infected donors (Spearman
correlation, r = 0.18, p = 0.01). Trend lines were generated using linear
regression analysis, and are shown in order to facilitate visualization of
correlations.
doi:10.1371/journal.ppat.1003041.g002
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expanded dataset of HLA-associated polymorphisms generated
from an analysis of 1899 gag sequences from Zambia and South
Africa (Carlson, Schaefer et al., manuscript in preparation),
described above, was employed. The number of non-consensus
polymorphisms located at HLA-associated positions was deter-
mined for each MJ4 chimera and then correlated with the RC
defined by those Gag sequences. Surprisingly, we found a positive
association between the number of HLA-associated polymor-
phisms and RC (Fig. 5A; r = 0.14, p = 0.05). Although counter-
intuitive, this is consistent with the fact that not all HLA-
associated polymorphisms within a particular Gag sequence will
necessarily reduce fitness. We have shown in the previous sections
that several non-adapted (or ‘‘susceptible’’ to HLA pressure)
HLA-associated polymorphisms increase fitness relative to the
median of all sequences. Indeed, we observe a highly statistically
significant positive correlation between the number of non-
adapted HLA-associated polymorphisms and RC (Spearman
correlation, r = 0.23, p = 0.003; data not shown). Thus, the
inclusion of both adapted (or escaped with respect to specific
HLA alleles) and non-adapted polymorphisms within this
expanded HLA-associated dataset may explain the observed
positive association between numbers of HLA-associated poly-
morphisms and RC. Therefore, we hypothesize that it is the
balance and interaction of both fitness increasing and fitness
decreasing polymorphisms within a particular sequence that
ultimately determines the RC of the virus.
In order to more accurately determine how the number and
quality of HLA-associated polymorphisms affects RC and to
correct for the opposing influence of both increasing and
decreasing polymorphisms within a particular sequence, a
summed polymorphism score was calculated by assigning fitness
increasing polymorphisms a score of +1, fitness decreasing
polymorphisms a score of 21, and neutral polymorphisms a score
of 0. HLA-associated polymorphisms were defined as being
positive, negative, or neutral based on the previously described
univariate analysis that correlated specific residues within our 149
sequences with changes in RC. In this modified analysis, we
observed a highly statistically significant correlation between the
summed polymorphism score and RC (Figure 5B: Spearman rank
correlation; r = 0.6, p =,0.0001), confirming that the sequence
features are approximately independent of each other and
suggesting that the offsetting influence of fitness decreasing and
increasing polymorphisms is a strong contributor to RC. This
finding may explain the observation that, in general, the most-fit
viruses are less like the consensus subtype C Gag sequence,
consistent with a majority of polymorphisms increasing fitness
(Figure S2, [55]).
Figure 3. Identification of polymorphisms in Gag that signif-
icantly affect RC, several of which can be linked to HLA-class I
alleles. (A) In a pair-wise analysis of all amino acids represented in the
149 gag sequences tested, we observed 49 amino acids at 31 unique
positions that were statistically associated (p,0.05) with changes in RC
(open circles RC decreasing, filled circles RC increasing), 3 of which were
significant at (q,0.2) when adjusted for multiple comparisons (red for
RC reducing and green for RC increasing). The x-axis shows the
polymorphism position in the primary Gag sequence (HXB2 number-
ing), and the y-axis depicts the impact of the polymorphism on RC
relative to the median RC of all viruses (,1.5). (B) In a separate study
analyzing 1899 subtype C gag sequences from Zambia and South
Africa, 199 residues were linked to HLA-I alleles (q,0.2, Carlson,
Schaefer et al., manuscript in preparation). From this, a total of 7
polymorphisms associated with changes in RC (p,0.05) were found to
be adapted to specific HLA-I alleles, adapted (amino acid is present
when HLA-I allele is also present.) (* denotes q,0.2). (C) Six
polymorphisms associated with changes in RC (p,0.05) were found
to be non-adapted (amino acid is present only when HLA-I allele is
absent) to specific HLA-I alleles (* denotes q,0.2).
doi:10.1371/journal.ppat.1003041.g003
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The cumulative and qualitative effect of HLA-associated
polymorphisms in Gag on set point viral load
In a previous report using 88 Zambian linked seroconverters,
we reported that increasing numbers of transmitted HLA-B
associated polymorphisms within or adjacent to well defined
epitopes were associated with lower set point VLs [50]. When we
expand this analysis to include all 149 Zambian linked recipients
and use the same dataset of HLA-linked polymorphisms used by
Goepfert et al. [50] we observe the same correlation (r =20.15,
p = 0.03, Figure 6A). However, when we use the expanded HLA-
associated data set (199 associations) to define HLA-associated
polymorphisms, we no longer observe a statistically significant
negative association between the number of transmitted HLA-
associated polymorphisms in Gag and set point VL (Figure 6B).
We therefore hypothesized that, as with RC, this correlation
between the total number of transmitted HLA-associated
polymorphisms in Gag and set point VL in newly infected
individuals may be confounded by not taking into account
Figure 5. The balance of fitness increasing and decreasing
HLA-associated polymorphisms strongly correlates with RC. (A)
The total number of HLA-associated polymorphisms positively corre-
lates with RC. HLA-associated polymorphisms were defined as non-
consensus residues at any amino acid position known to have
polymorphisms statistically linked to HLA-I alleles. (B) RC of Gag-MJ4
chimeras is highly correlated to the summed polymorphism score in
Gag. Each amino acid polymorphism was given a score of 1 (fitness
increasing) or 21 (fitness decreasing). Summed polymorphism scores
were generated by summing these scores for each Gag protein. Trend
lines were generated using linear regression analysis, and are shown in
order to facilitate visualization of correlations.
doi:10.1371/journal.ppat.1003041.g005
Figure 4. Rare polymorphisms have a significantly greater
impact on RC. (A) In an exploratory analysis, rare fitness reducing
polymorphisms, occurring in less than 10 out of 149 of the sequences
tested, were found to decrease fitness to a significantly greater degree
than more common fitness decreasing mutations (Mann Whitney U test,
p = 0.002). The y-axis depicts the impact of the polymorphism on RC
relative to the median RC of all viruses (,1.5) (B) Rare fitness increasing
polymorphisms, occurring in less than 10 out of 149 of the sequences
tested, were found to increase fitness to a significantly greater degree
than more common ones (Mann Whitney U test, p = 0.0002).
doi:10.1371/journal.ppat.1003041.g004
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whether polymorphisms increase or decrease fitness. Indeed, using
the summed polymorphism score, we observe a highly significant
correlation between the summed score of HLA-associated
polymorphisms and set point VL (Figure 6C: r = 0.21,
p = 0.006). This demonstrates that it is not merely the quantity
of HLA-associated polymorphisms present in the transmitted Gag
sequence that ultimately defines set point VL, but it is the
influence of both fitness increasing and decreasing polymorphisms
that contributes to RC and in turn set point VL in newly infected
individuals.
Transmission of viruses with low replicative capacities
provides recipients with a longer-term clinical benefit
Though set point VL has been shown to be a relevant marker
for disease progression [67,68], CD4+ T cell counts are
traditionally used to define those individuals that have progressed
to AIDS and are at a higher risk for opportunistic infections
[69,70]. Therefore, we analyzed a subset of individuals (n = 66) for
whom longitudinal CD4+ T cells counts for at least one-year post-
infection are available. We observed a statistically significant
correlation between the average CD4+ T cell counts and the
replicative capacities of Gag-MJ4 chimeras (Figure 7A, Spearman
correlation, r =20.24, p = 0.02). This demonstrates that infection
with attenuated viruses may impart some survival benefit to newly
infected individuals, at least within the first year of infection.
Subsequently, we determined whether individuals infected with
poorly replicating viruses exhibit differential pathogenesis over the
first three years of infection or whether this early benefit is
transient and quickly lost. To answer this question, we studied a
subset of the linked recipients (n = 63) for whom CD4+ T cell
counts were available at regular three month intervals for greater
than one year post-infection.
In a Kaplan-Meier survival analysis, in which we defined the
endpoint as having a CD4+ T cell count .350 cells/mm3 (WHO
recommendation for initiation of anti-retroviral therapy [71]), we
observed a statistically significant difference in the number of
individuals that maintain CD4+ counts .350 cells/mm3 between
those infected with viruses that replicate very poorly (RC,1) and
those infected with highly replicating viruses (RC.2), within the
first 3 years of infection (Figure 7B, Mantel-Cox test p = 0.029).
This disparity in disease progression was even more pronounced
when the endpoint was defined as having CD4+ T cell counts
.300 cells/mm3, demonstrating a median difference of 896 days
before falling below the CD4+ count cut off between individuals
infected with low and high replicating viruses (Figure 7C, Mantel-
Cox test p = 0.014). Using a Cox proportional hazard model, we
demonstrate a significantly increased risk of CD4+ T cell counts
falling below 350 (Hazard Ratio (HR) 2.36; p = 0.034) or 300 (HR
3.80; p = 0.021) over the first three years of infection for
individuals whose Gag conferred an RC.2 vs. RC,1.
Interestingly, the benefit conferred by low replicating viruses
could not be wholly explained by differences in set point VL within
this smaller data set. Although there was a trend towards higher
VLs between the two most disparate groups, with a 2.5 fold
difference in median VLs (Figure 7D), we observed no statistically
significant differences in median set point VLs between individuals
infected with low (RC,1), medium (RC = 1–2), and highly
(RC.2) replicating viruses. Further, in Cox proportional hazard
Figure 6. The balance of HLA-associated fitness increasing and
decreasing mutations strongly correlates with set point viral
load in newly infected individuals. (A) The number of HLA-
associated amino acid polymorphisms within well-defined epitopes for
each Gag protein negatively correlates with set point VL. (B) The total
number of HLA-associated polymorphisms (including those outside
well-defined CTL epitopes) in Gag does not correlate to set point VL in
newly infected individuals. (C) When the quality of HLA-associated
polymorphisms is considered, a strong correlation between the
summed polymorphism score (as defined in Figure 5) and set point
VL is observed. Trend lines were generated using linear regression
analysis, and are shown in order to facilitate visualization of correlations.
doi:10.1371/journal.ppat.1003041.g006
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models that take into account VL, the HR remained high (2.18
and 3.12 respectively) and p values continued to trend or remain
borderline significant (p = 0.093 and 0.051) (Table 2), indicating
that both VL and RC can independently affect CD4 loss.
Moreover, the HR associated with log10 increases in set point
VL alone was lower than that for RC alone (HR = 1.75 versus
2.62, and 2.09 versus 3.80; CD4 ,350 and 300 respectively;
Table 2). These results suggest that infection with a low replicating
virus confers clinical benefit outside of the effect of RC on set point
VL, and that the kinetics of viral replication early in infection can
ultimately dictate long-term pathogenesis.
Discussion
In this study of 149 linked Zambian heterosexual transmission
pairs from the ZEHRP discordant couple cohort we have more
fully characterized the role that HIV-1 viral characteristics, in
particular the replicative capacity (RC) conferred by the trans-
mitted gag sequence, plays in defining parameters of early HIV-1
pathogenesis. Identification and comparison of both donor and
recipient gag sequences for all 149 transmission pairs revealed a
high degree of similarity (97.6%) within each linked pair, allowing
us to conclude that the majority of polymorphisms in Gag present
at the seroconversion time point were transmitted from the
chronically infected donor.
Transmitted gag sequences from newly infected
individuals engineered into MJ4 drastically alters
replicative capacity
Since all of the transmission pairs in this study were infected
with subtype C viruses, our approach of precisely cloning gag genes
from acutely-infected recipients into a primary isolate (MJ4)
provirus has many important advantages over previously em-
ployed methods. MJ4 is a CCR5 tropic infectious molecular clone
derived from a subtype C clinical isolate from Botswana, providing
greater homology to viruses circulating within the Zambian
population than other previously used subtype B lab-adapted
strains [33,47,54,55]. Additionally, this cloning method for
generating Gag-MJ4 chimeric viruses does not rely on recombi-
nation based technologies that require the outgrowth of viral
quasispecies, which may select for the most fit virus, and in some
cases, amino acid changes in the viral stocks that are not present in
the individual from which they were derived [32,47,53–55]. The
use of a common BclI restriction site located 137 nucleotides after
the gag stop codon in MJ4 does result in a chimeric protease,
Figure 7. RC affects the rate of CD4 decline in a manner that
may be independent of viral load. (A) In a subset of individuals for
which longitudinal CD4+ counts were available for at least 1 year post
infection (n = 63), RC of Gag-MJ4 chimeras negatively correlated with
the average CD4+ counts of linked recipients within the first year
(Spearman rank correlation, r =20.24, p = 0.02). (B) Kaplan-Meier plots
in which the endpoint was defined as the first CD4+ count below 350.
Interval cut-off for endpoint was set to 36 months. The difference in
median time to endpoint between those receiving viruses with RC,1
(n = 14) and RC.2 (n = 20) was 384 days (Log-rank test, p = 0.029). (C)
Kaplan-Meier plots in which the endpoint was defined as the first CD4+
count below 300. Interval cut-off for endpoint was set to 36 months.
The difference in median time to endpoint between those receiving
viruses with RC,1 (n = 14) and RC.2 (n = 20) was .800 days (Log-rank
test, p = 0.014). (D) The difference in median VL between RC groups
RC,1, RC 1–2, and RC .2 were not significantly different (Mann
Whitney U test), consistent with the effect of RC on CD4 decline being
independent of VL.
doi:10.1371/journal.ppat.1003041.g007
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however, this region is 96.5% conserved in this cohort and we did
not observe a high prevalence of dead or inactive Gag-MJ4
chimeras.
The impact of engineering foreign gag sequences into MJ4 on
virus replication was highly significant, with many of the chimeras
exhibiting RC values greater than a hundred-fold higher than
wild-type MJ4, which in this assay is one of the poorer replicators.
This indicates that substitution of Gag can drastically alter the in
vitro RC of the virus when all other viral components are constant.
Multiple intra-molecular contacts as well as host protein interac-
tions in Gag are necessary for effective intracellular Gag trafficking
[72,73], particle formation [74], budding [75,76], maturation [77]
and disassembly [78]. Therefore, immune mediated adaptation of
this functionally constrained protein could have clear consequenc-
es for viral replication through disruption of these many
interactions.
Correlation between the replicative capacities conferred
by transmitted gag sequences and viral loads in newly
infected individuals and their transmitting partners
It has been well established that the set point VL in those
recently infected with HIV-1 is correlated to disease progression
and clinical outcome [67,68]. Previous data from our group
demonstrated that transmission of sequences with increasing
numbers of CTL escape mutations in Gag resulted in lower set
point VLs in newly infected individuals, a finding that suggested
that transmitted HLA-associated polymorphisms in Gag might
negatively affect viral replication [50]. We have confirmed this
association in the current study after increasing the number of
transmission pairs analyzed from 88 to 149. This result is
consistent with studies by Brockman et al., which have demon-
strated a statistically significant link between the RC conferred by
gag-pro genes in subtype B and C chronically infected individuals to
VL [43,47,54,55]. However, a statistically significant correlation
between Gag RC derived from acutely infected individuals and set
point VL has not previously been definitively reported in a subtype
C cohort.
In contrast, in this large group of very early ZEHRP
seroconvertors (with samples drawn a median of 45 days post-
EDI) we observed a clear statistically significant correlation
(p = 0.02) between the RC conferred by the transmitted gag
sequence and the early set point VL in newly infected individuals.
This result implies that RC plays a role in defining the overall level
of virus replication during the first year of infection. Moreover, in
multivariable analyses that take into account the early viral control
imposed by the B*57 allele and by gender, the impact of RC on set
point VL was found to be independent of these two host factors
(p = 0.009). Other factors such as NK cells and restriction factors
such as TRIM or APOBEC may potentially affect RC and VL,
however little is currently known regarding these potential effects,
and future efforts should evaluate the role of such factors. While
we observed a statistically significant positive correlation between
RC and set point VL, outliers in the data exist that do not fit the
trend, and in some cases can be explained by the presence of
protective HLA-alleles or by a large number of escape mutations
present in the transmitted sequence that are relevant to the HLA
background of the newly infected individual. Set point VL is
clearly determined by a combination of both host factors,
including HLA-alleles, and viral factors such as RC, and this
may explain the differences in the absolute correlation for each
individual.
The RC of Gag-MJ4 chimeras also correlated with VLs near
the estimated date of infection in chronically infected donors,
consistent with the previously reported observation that donor and
recipient VLs are correlated within epidemiologically linked
transmission pairs [11–13]. The data presented here would
suggest that the RC conferred by the transmitted Gag sequence
is a contributing viral characteristic of that donor virus responsible
for influencing early set point VL in the newly infected partner.
Several amino acids in Gag significantly correlate to
changes in replicative capacity
In a pair-wise analysis, a large number of residues were
associated with changes in fitness (p,0.05, q,0.51), with 4
residues at 3 unique positions at q,0.2. These residues included
the polymorphisms 30R and 31I in p17 (MA), and 309S in p24
(CA). However, in an exploratory analysis of those residues
associated with changes in RC with a p value,0.05, it was clear
that associated polymorphisms were noticeably enriched on a per
residue basis in p17 and p2 (Fisher’s exact test, p,0.001). The
former plays critical roles in intracellular trafficking, and
membrane association of Gag [73,79,80], while the latter is an
important structural element involved in formation of the
immature protein shell [81,82] and a target of the novel drug
Bevirimat during maturational cleavage of the Gag precursor
[83,84]. Surprisingly, only one third of the associated mutations
negatively affected virus replication, while nearly two-thirds of the
associations increased fitness. Some of these fitness-increasing
Table 2. Cox proportional hazard models demonstrate the independent effects of RC and VL on CD4 decline.
Risk of CD4 below 350 in first 3 years p Hazard Ratioc lower .95d upper .95d
RC.2a 0.034 2.62 1.077 6.374
Log10(SetPoint VL)b 0.04 1.75 1.014 3.004
RC.2+Log10(SetPointVL) 0.093 2.18 0.878 5.395
Risk of CD4 below 300 in first 3 years p Hazard Ratioc lower .95d upper .95d
RC.2a 0.021 3.80 1.226 11.801
Log10(SetPoint VL)b 0.023 2.09 1.105 3.94
RC.2+log10(SetPointVL) 0.051 3.12 0.995 9.751
aas compared to RC,1.
bModel in which log10 set point viral load in the linked recipient is taken into account.
cThe ratio of hazard rates between the variables RC.2 and RC,1.
dThe upper and lower bounds of confidence.
doi:10.1371/journal.ppat.1003041.t002
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mutations represent adapted polymorphisms (i.e. selected as
immune escape) and in terms of vaccine design it may be
important to avoid the inclusion of such epitopes.
Polymorphisms positively or negatively affecting replication in
the p24 region of Gag were limited to just six residues (4 positive, 2
negative), in accordance with the conserved nature of this protein.
Surprisingly, none of the canonical B*57/B*5801 associated
escape mutations within p24, whose fitness defects have been well
documented [24,31–34], were found to be significantly associated
with decreases in RC in our present study. This may be due to the
high prevalence of B*57/B*5801 positive individuals within this
cohort (25%), which could promote viral adaptation to these
alleles over time through compensatory mutations [22]. It is also
possible that some fitness defects such as those associated with
T242N within the TW10 epitope might be missed in the current
study, as a previous study has shown that it is cell-type dependent
[32].
The most deleterious HLA-associated mutation that we
observed was K12E, which reduced RC by almost 10-fold relative
to the median RC of the cohort. This polymorphism is found quite
rarely in the population (3 out of 149), and is statistically associated
with HLA-A*74, an allele found to be highly protective in both
this Zambian subtype C cohort as well as others [9,85]. The
protective effect of A*74 has recently been demonstrated to be
independent of HLA-B*57 [86]. The negative in vitro impact of
mutations at residue 12 on replication is supported by a
longitudinal study of a subset of this seroconvertor cohort
(n = 81), in whom polymorphisms at residue 12 were found to
revert at a high rate (25%/yr), over the first two years of infection
(Schaefer et al., manuscript in preparation). Furthermore, in this
same study, escape at position 12 occurred only once and at 24
months post-infection in a total of ten A*74 positive individuals,
confirming the high fitness cost associated with CTL-induced
escape mutations at this position. We hypothesize that the
targeting of this putative epitope, KR9 [86], may account for
part of the protective effect conferred by A*74 and indicates that
protective immune responses can target regions of Gag outside of
p24. While the nature of the replication defect in viruses encoding
K12E remains to be determined, this residue does lie in the highly
basic region at the N-terminus of p17 (MA), which is involved in
membrane targeting and membrane association of Gag
[80,87,88].
Rare polymorphisms have the greatest effect on
replicative capacity
Rare mutations, such as K12E, which occur in a small subset of
the population studied here (less than 10 individuals of the 149),
affected fitness to a statistically greater degree than more common
polymorphisms. Rare fitness decreasing mutations are likely
unique to specific circumstances such as those where a consider-
able decrease in RC is warranted in the face of a very effective
cellular immune response that is largely abrogated upon mutation.
Such mutations have been found to subsequently revert after
transmission to individuals lacking the selecting HLA-allele
[17,42,89] and in whom they now confer a fitness deficit for the
virus. These sites of rare fitness reducing polymorphisms may
emphasize vulnerable epitopes at which HIV-1 escapes from
immune pressure with great difficulty. Alternatively, it is possible
that, when escape occurs, it is consistently associated with a
decrease in RC that cannot be completely compensated.
A similar observation was made for rare mutations that greatly
increase RC. Global compensatory mutations do exist that can
compensate multiple deleterious mutations, such as those within
the cyclophilin binding loop [42,46]. Some of the rare fitness
increasing mutations may be of this type, although those reported
previously have generally been quite common in the population.
Compensatory mutations can also be secondary site-suppressors of
deleterious mutations [90]. Frequently, such mutations are only
conditionally beneficial and can be deleterious in a different
context, which could explain why some fitness increasing
mutations are rare. It is also possible that these mutations do
carry some unrecognized in vivo fitness cost that cannot be
captured in the in vitro replication system used here. Due to the fact
that these mutations are rare, they are difficult to statistically link
to HLA alleles or to link to other residues with which they may
covary, making the potential fitness defects that these mutations
mitigate difficult to elucidate.
The cumulative and qualitative effect of HLA associated
polymorphisms in Gag on replicative capacity and VL
A key goal of this study was to understand how the cellular
immune response might select for mutations in Gag that reduce
viral RC, and while identification of specific amino acid
polymorphisms that either increase or decrease fitness can be
informative, it is equally important to elucidate how the
accumulation of specific HLA-associated polymorphisms in Gag
affects both RC of the virus and VL in the newly infected person.
Previous efforts to correlate the total number of HLA-associated
polymorphisms in Gag to RC have yielded inconclusive results
[32,54], perhaps because the quality of the polymorphisms in
question was not considered. Using an expanded list of HLA-
associated polymorphisms (Carlson, Schaefer et al., manuscript in
preparation) we report a weak positive correlation between the
total number of HLA-associated polymorphisms in Gag and RC.
The fact that this correlation was positive is consistent with our
observation that a large fraction of the non-consensus HLA-
associated polymorphisms increased RC. In particular, in the
expanded data set of HLA-associated polymorphisms, we observed
that non-adapted residues, which would be predicted to render the
virus susceptible to the linked HLA allele, were statistically
associated with increased fitness.
These findings suggest that CTL escape mutations, which
decrease the overall RC of the virus, are being driven to consensus
as a result of population level immune pressure. In the absence of
immune pressure, the non-escaped (non-adapted) residues would
be expected to predominate, but if they render the virus
susceptible to a large portion of the population, then the consensus
residue will be escaped rather than susceptible, despite reducing in
vitro fitness. This is consistent with the findings of Kawashima et al.
[22] that the frequency of certain HLA-class I alleles within a
particular population can influence the fixation of escape
mutations in the overall population. Moreover, Wright et al. [55]
showed that Gag-NL43 recombinant viruses encoding gag-pro
sequences most disparate from the subtype C consensus gag-pro
sequence had statistically higher replicative capacities than their
more consensus-like counterparts, and this finding has been
recapitulated in this current study. Taken together, these data
suggest that overall, HLA-mediated adaptation is driving the
fixation of consensus residues that are less fit than their susceptible
counter-parts.
When we account for this ability of HLA-associated polymor-
phisms to either increase or decrease fitness by assigning a
summed polymorphism score, which subtracts the number of
fitness decreasing polymorphisms from the number of fitness
increasing polymorphisms in a particular sequence, we find a
highly statistically significant correlation between RC and the
summed polymorphism score (p,0.0001). Although this p-value
should be interpreted cautiously, since it reflects the summation of
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features previously identified to be correlated with RC, the data do
suggest that the effect of polymorphisms is cumulative, and that as
a Gag sequence accumulates an excess of fitness-reducing
polymorphisms, the RC decreases proportionally. Similarly,
utilization of a summed polymorphism score improved previously
reported correlations between the total number of HLA-associated
polymorphisms in Gag and set point VL in newly infected
individuals [50]. We observed a highly statistically significantly
correlation (p = 0.006) between the summed polymorphism score
and set point VL in newly infected individuals. Just as this balance
of fitness increasing and decreasing polymorphisms impacts RC, it
simultaneously influences the set point VL of the newly infected
individual.
Transmission of viruses with low RCs provides recipients
with a longer-term clinical benefit
While VL has been demonstrated to influence the rate of disease
progression in HIV-1 infected individuals [68,69], it is possible
that, during the very earliest stages of infection and before host
immune control, the replication rate of the virus may affect the
rate of future damage to the immune system. Indeed, we observed
a statistically significant negative correlation between RC and
average CD4 counts for the first year post infection, suggesting a
role for RC in defining this important parameter of pathogenesis
at early stages after infection. However, it is possible that this early
benefit could be quickly lost due to further adaptation of the virus
to the new host’s immunogenetic background and further
compensation for de novo escape mutations. Consequently, we
analyzed individuals with longitudinal CD4 counts out to three-
years post infection in order to determine if the observed early
benefit was sustained in early chronic stages of infection. Using
Kaplan-Meier survival analyses to examine the relative time for
individuals infected with viruses encoding gag genes conferring RC
values of ,1 and .2 to reach CD4 T cell counts of 350 after 3
years of infection, we observed a clear and statistically significant
difference. This was even more striking when CD4 counts less than
300 were used as the endpoint. Moreover a Cox proportional
hazard model demonstrated a significantly increased risk of CD4
counts falling below both 350 (HR 2.36) or 300 (HR 3.80) over the
first three years of infection for individuals whose gag gene
conferred an RC.2 vs. RC,1. These findings indicate that the
RC conferred by the transmitted Gag sequence may have
profound and prolonged effects on HIV-1 pathogenesis from
acute to early chronic stages of infection.
While RC and VL are correlated in the full data set, set point
VL does not fully explain the effect of RC on CD4, because we did
not observe any statistically significant differences in set point VL
between the two groups (RC,1 and RC.2) for the subset of
individuals with CD4+T cell counts (n = 63). Moreover, in Cox
proportional hazard models which take into account VL, the HR
remained high (2.17 and 3.11 respectively) and p values continued
to trend or remain borderline significant (p = 0.093 and 0.051).
This suggests that both VL and RC have independent effects on
CD4 decline, however, because this analysis was conducted on a
subset of less than half of our initial cohort, additional work is
underway to further confirm and extend these results.
It seems possible, therefore, that the RC of the transmitted
variant may initiate crucial events, early in infection and
dissemination, that dictate both acute and later stage pathogenesis
regardless of the ability of the immune system to control viral
replication down to set point. Infection with highly replicating
variants could lead to a more complete depletion of central
memory CD4+ T cell pools at this early time that could predispose
an individual to more rapid CD4+ T cell loss, irrespective of
adequate control of viral replication. This is evidenced in a few
individuals infected with highly replicating Gag variants (RC.2),
who go on to control VL to a low set point, but whose CD4+ T
cells counts rapidly drop below 300 (data not shown). Additionally,
a high level of peak viremia or initial high antigen loads could
establish an inflammatory environment that leads to sustained
immune activation, which has been implicated as a more reliable
marker for disease progression [91]. These possibilities are the
focus of ongoing work.
In summary, using an in vitro approach to define the impact of
polymorphisms in Gag on transmitted virus RC has clearly shown
that this property of the virus is a significant contributor to early
set point VL in a newly infected individual. More importantly,
however, these studies suggest a critical role for RC in defining the
trajectory of immune depletion and pathogenesis, beyond simply
its impact on VL, and highlight the importance of the very earliest
events in virus-host interactions. It also raises the possibility that a
vaccine that can attenuate early virus replication would have a
positive impact both on vaccinated individuals, as well as non-
vaccinated individuals by weakening the transmitted/founder
virus and increasing the likelihood of transmission of low
replicating variants.
Supporting Information
Figure S1 Donor and recipient population gag sequenc-
es cluster with one another. Gag population sequences from
donors and linked recipients were amplified and sequenced as
described in the methods section. Nucleotide gag sequences were
aligned using the Gene Cutter tool accessible on the Los Alamos
Nation Lab HIV Sequence Database (http://www.hiv.lanl.gov/
content/sequence/GENE_CUTTER/cutter.html) and a neigh-
bor-joining tree was generated using the Geneious sequence
analysis software v5.5.7 (Biomatters Ltd.). The radial tree was
annotated using the Interactive Tree of Life (iTOL) online tool for
phylogenetic tree display and annotation (Letunic and Bork,
Bioinformatics, 2006). Blue denotes transmitting partners (donors)
and green denotes linked recipients. This tree demonstrates the
high degree of similarity between donor and linked recipient gag
population sequences within epidemiologically linked transmission
pairs.
(EPS)
Figure S2 Gag sequences that are less like the Gag
subtype C consensus sequence replicate more efficiently
in vitro. The Gag amino acid sequences of all Gag-MJ4 chimeras
were compared to a Zambian subtype C consensus Gag sequence
(generated using the LANL Consensus Maker tool; http://www.
hiv.lanl.gov/content/sequence/CONSENSUS/consensus.html)
by building a neighbor-joining tree using the Geneious sequence
analysis software v5.5.7 (Biomatters Ltd.) and the percent similarity
to consensus was determined for each sequence. Notably, viruses
encoding Gag sequences most disparate from the subtype C
consensus Gag sequence replicated to higher levels, and we
observed a statistically significant negative correlation between
RC and the percent similarity of Gag to consensus (Pearson
correlation, p = 0.002, r =20.23).
(EPS)
Table S1 Amino acids in Gag associated with changes in
replicative capacity. This table lists all amino acids associated
with changes in RC. Residues that remain significantly associated
with changes in RC after correction for multiple comparisons
(q,0.2) are depicted in green. A total of 152 sequences and RC
values were available for association analysis, with 149 of these
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with sufficient clinical follow-up for inclusion in the broader study.
a DRC is defined as median RC of all viruses tested (,1.5)
subtracted from the median RC of all viruses with the particular
polymorphism. b The location of epitopes was defined by the
compendium of ‘‘A-list’’ epitopes available in the LANL
Immunology Database (HIV Molecular Immunology 2009). c HLA
class I alleles restricting epitopes harboring these polymorphisms
that affect RC were also defined base on the LANL Immunology
Database compilation of ‘‘A-list’’ epitopes.
(DOC)
Acknowledgments
The investigators thank all the volunteers in Zambia who participated in
this study and all the staff at the Zambia Emory HIV Research Project in
Lusaka who made this study possible. The investigators would like to thank
Jon Allen, Smita Chavan, and Mackenzie Hurlston for technical assistance
and sample management. We would also like to thank Dr. Mark Brockman
for his discussions and generous donation of the GXR25 cells.
Author Contributions
Conceived and designed the experiments: EH DTC JLP SAV PG JMC.
Performed the experiments: DTC JLP MS. Analyzed the data: EH DTC
JLP JMC DH TY JT RAK MAP HAP PG SAA. Contributed reagents/
materials/analysis tools: LY PF RAK JT SL JM WK JG SAA. Wrote the
paper: DTC JLP EH CAD JMC. Were critically involved in sample
collection, site maintenance, participant recruitment and follow-up: SL JM
WK JG SAA.
References
1. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008)
Identification and characterization of transmitted and early founder virus
envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552–
7557.
2. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, et al.
(2009) Inflammatory genital infections mitigate a severe genetic bottleneck in
heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 5:
e1000274.
3. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004)
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual trans-
mission. Science 303: 2019–2022.
4. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. (2007) A whole-
genome association study of major determinants for host control of HIV-1.
Science 317: 944–947.
5. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, et al. (1996) Influence of
combinations of human major histocompatibility complex genes on the course of
HIV-1 infection. Nat Med 2: 405–411.
6. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004)
Dominant influence of HLA-B in mediating the potential co-evolution of HIV
and HLA. Nature 432: 769–775.
7. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, et al. (2010) The major
genetic determinants of HIV-1 control affect HLA class I peptide presentation.
Science 330: 1551–1557.
8. Tang J, Kaslow RA (2003) The impact of host genetics on HIV infection and
disease progression in the era of highly active antiretroviral therapy. AIDS 17
Suppl 4: S51–60.
9. Tang J, Malhotra R, Song W, Brill I, Hu L, et al. (2010) Human leukocyte
antigens and HIV type 1 viral load in early and chronic infection: predominance
of evolving relationships. PLoS One 5: e9629.
10. Tang J, Tang S, Lobashevsky E, Myracle AD, Fideli U, et al. (2002) Favorable
and unfavorable HLA class I alleles and haplotypes in Zambians predominantly
infected with clade C human immunodeficiency virus type 1. J Virol 76: 8276–
8284.
11. Tang J, Tang S, Lobashevsky E, Zulu I, Aldrovandi G, et al. (2004) HLA allele
sharing and HIV type 1 viremia in seroconverting Zambians with known
transmitting partners. AIDS Res Hum Retroviruses 20: 19–25.
12. Hollingsworth TD, Laeyendecker O, Shirreff G, Donnelly CA, Serwadda D, et
al. (2010) HIV-1 transmitting couples have similar viral load set-points in Rakai,
Uganda. PLoS Pathog 6: e1000876.
13. Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, et al. (2010) HIV
RNA level in early infection is predicted by viral load in the transmission source.
AIDS 24: 941–945.
14. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, et al. (2009) Escape from
autologous neutralizing antibodies in acute/early subtype C HIV-1 infection
requires multiple pathways. PLoS Pathog 5: e1000594.
15. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, et al. (1997) Antiviral
pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during
primary infection demonstrated by rapid selection of CTL escape virus. Nat
Med 3: 205–211.
16. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, et al. (1997) Late
escape from an immunodominant cytotoxic T-lymphocyte response associated
with progression to AIDS. Nat Med 3: 212–217.
17. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV
evolution: CTL escape mutation and reversion after transmission. Nat Med 10:
282–289.
18. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, et al. (1991)
Human immunodeficiency virus genetic variation that can escape cytotoxic T
cell recognition. Nature 354: 453–459.
19. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, et al. (1997)
Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during
primary infection. Proc Natl Acad Sci U S A 94: 1890–1895.
20. Jones NA, Wei X, Flower DR, Wong M, Michor F, et al. (2004) Determinants of
human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic
T lymphocyte response. J Exp Med 200: 1243–1256.
21. Goulder PJ, Watkins DI (2004) HIV and SIV CTL escape: implications for
vaccine design. Nat Rev Immunol 4: 630–640.
22. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, et al. (2009)
Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458: 641–645.
23. Allen TM, Altfeld M, Yu XG, O’Sullivan KM, Lichterfeld M, et al. (2004)
Selection, transmission, and reversion of an antigen-processing cytotoxic T-
lymphocyte escape mutation in human immunodeficiency virus type 1 infection.
J Virol 78: 7069–7078.
24. Chopera DR, Woodman Z, Mlisana K, Mlotshwa M, Martin DP, et al. (2008)
Transmission of HIV-1 CTL escape variants provides HLA-mismatched
recipients with a survival advantage. PLoS Pathog 4: e1000033.
25. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, et al. (2004)
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med
10: 275–281.
26. Li B, Gladden AD, Altfeld M, Kaldor JM, Cooper DA, et al. (2007) Rapid
reversion of sequence polymorphisms dominates early human immunodeficiency
virus type 1 evolution. J Virol 81: 193–201.
27. Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R, et al. (2008)
Central role of reverting mutations in HLA associations with human
immunodeficiency virus set point. J Virol 82: 8548–8559.
28. Rousseau CM, Daniels MG, Carlson JM, Kadie C, Crawford H, et al. (2008)
HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c
proteome: immune escape and viral load. J Virol 82: 6434–6446.
29. Schneidewind A, Brockman MA, Sidney J, Wang YE, Chen H, et al. (2008)
Structural and functional constraints limit options for cytotoxic T-lymphocyte
escape in the immunodominant HLA-B27-restricted epitope in human
immunodeficiency virus type 1 capsid. J Virol 82: 5594–5605.
30. Dahirel V, Shekhar K, Pereyra F, Miura T, Artyomov M, et al. (2011)
Coordinate linkage of HIV evolution reveals regions of immunological
vulnerability. Proc Natl Acad Sci U S A 108: 11530–11535.
31. Boutwell CL, Rowley CF, Essex M (2009) Reduced viral replication capacity of
human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-
lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J Virol 83:
2460–2468.
32. Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, et al. (2007)
Escape and compensation from early HLA-B57-mediated cytotoxic T-
lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid
interactions with cyclophilin A. J Virol 81: 12608–12618.
33. Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, et al. (2007)
Compensatory mutation partially restores fitness and delays reversion of escape
mutation within the immunodominant HLA-B*5703-restricted Gag epitope in
chronic human immunodeficiency virus type 1 infection. J Virol 81: 8346–8351.
34. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, et al. (2006) Fitness
cost of escape mutations in p24 Gag in association with control of human
immunodeficiency virus type 1. J Virol 80: 3617–3623.
35. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, et al. (2007) Escape
from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag
is associated with a dramatic reduction in human immunodeficiency virus type 1
replication. J Virol 81: 12382–12393.
36. Wright JK, Naidoo VL, Brumme ZL, Prince JL, Claiborne DT, et al. (2012)
Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication
capacity. J Virol 86: 3193–3199.
37. Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, et al. (2011) Definition
of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 9:
208.
38. Rolland M, Heckerman D, Deng W, Rousseau CM, Coovadia H, et al. (2008)
Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral
loads. PLoS One 3: e1424.
HIV-1 Replicative Capacity and Early Pathogenesis
PLOS Pathogens | www.plospathogens.org 14 November 2012 | Volume 8 | Issue 11 | e1003041
39. Wang YE, Li B, Carlson JM, Streeck H, Gladden AD, et al. (2009) Protective
HLA class I alleles that restrict acute-phase CD8+ T-cell responses are
associated with viral escape mutations located in highly conserved regions of
human immunodeficiency virus type 1. J Virol 83: 1845–1855.
40. Wagner R, Leschonsky B, Harrer E, Paulus C, Weber C, et al. (1999) Molecular
and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized
from a long-term nonprogressor: constraints on immune escape associated with
targeting a sequence essential for viral replication. J Immunol 162: 3727–3734.
41. Peyerl FW, Barouch DH, Letvin NL (2004) Structural constraints on viral escape
from HIV- and SIV-specific cytotoxic T-lymphocytes. Viral Immunol 17: 144–
151.
42. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, et al. (2009) Evolution
of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals
and their transmission recipients. J Exp Med 206: 909–921.
43. Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, et al. (2010) Early
selection in Gag by protective HLA alleles contributes to reduced HIV-1
replication capacity that may be largely compensated for in chronic infection.
J Virol 84: 11937–11949.
44. Carlson JM, Brumme ZL, Rousseau CM, Brumme CJ, Matthews P, et al. (2008)
Phylogenetic dependency networks: inferring patterns of CTL escape and codon
covariation in HIV-1 Gag. PLoS Comput Biol 4: e1000225.
45. Chopera DR, Mlotshwa M, Woodman Z, Mlisana K, de Assis Rosa D, et al.
(2011) Virological and immunological factors associated with HIV-1 differential
disease progression in HLA-B 58:01-positive individuals. J Virol 85: 7070–7080.
46. Crawford H, Matthews PC, Schaefer M, Carlson JM, Leslie A, et al. (2011) The
hypervariable HIV-1 capsid protein residues comprise HLA-driven CD8+ T-cell
escape mutations and covarying HLA-independent polymorphisms. J Virol 85:
1384–1390.
47. Huang KH, Goedhals D, Carlson JM, Brockman MA, Mishra S, et al. (2011)
Progression to AIDS in South Africa is associated with both reverting and
compensatory viral mutations. PLoS One 6: e19018.
48. Rolland M, Carlson JM, Manocheewa S, Swain JV, Lanxon-Cookson E, et al.
(2010) Amino-acid co-variation in HIV-1 Gag subtype C: HLA-mediated
selection pressure and compensatory dynamics. PLoS One 5: e12463.
49. Schneidewind A, Brumme ZL, Brumme CJ, Power KA, Reyor LL, et al. (2009)
Transmission and long-term stability of compensated CD8 escape mutations.
J Virol 83: 3993–3997.
50. Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, et al. (2008)
Transmission of HIV-1 Gag immune escape mutations is associated with
reduced viral load in linked recipients. J Exp Med 205: 1009–1017.
51. Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, et al. (2010) Impaired
replication capacity of acute/early viruses in persons who become HIV
controllers. J Virol 84: 7581–7591.
52. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, et al. (2009)
HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select
for rare gag variants associated with reduced viral replication capacity and
strong cytotoxic T-lymphocyte [corrected] recognition. J Virol 83: 2743–2755.
53. Miura T, Brockman MA, Brumme ZL, Brumme CJ, Pereyra F, et al. (2009)
HLA-associated alterations in replication capacity of chimeric NL4-3 viruses
carrying gag-protease from elite controllers of human immunodeficiency virus
type 1. J Virol 83: 140–149.
54. Wright JK, Novitsky V, Brockman MA, Brumme ZL, Brumme CJ, et al. (2011)
Influence of Gag-protease-mediated replication capacity on disease progression
in individuals recently infected with HIV-1 subtype C. J Virol 85: 3996–4006.
55. Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, et al. (2010)
Gag-protease-mediated replication capacity in HIV-1 subtype C chronic
infection: associations with HLA type and clinical parameters. J Virol 84:
10820–10831.
56. Ndung’u T, Renjifo B, Essex M (2001) Construction and analysis of an infectious
human Immunodeficiency virus type 1 subtype C molecular clone. J Virol 75:
4964–4972.
57. Allen S, Karita E, Chomba E, Roth DL, Telfair J, et al. (2007) Promotion of
couples’ voluntary counselling and testing for HIV through influential networks
in two African capital cities. BMC Public Health 7: 349.
58. Kempf MC, Allen S, Zulu I, Kancheya N, Stephenson R, et al. (2008)
Enrollment and retention of HIV discordant couples in Lusaka, Zambia.
J Acquir Immune Defic Syndr 47: 116–125.
59. McKenna SL, Muyinda GK, Roth D, Mwali M, Ng’andu N, et al. (1997) Rapid
HIV testing and counseling for voluntary testing centers in Africa. AIDS 11
Suppl 1: S103–110.
60. Trask SA, Derdeyn CA, Fideli U, Chen Y, Meleth S, et al. (2002) Molecular
epidemiology of human immunodeficiency virus type 1 transmission in a
heterosexual cohort of discordant couples in Zambia. J Virol 76: 397–405.
61. Bhakta SJ, Shang L, Prince JL, Claiborne DT, Hunter E (2011) Mutagenesis of
tyrosine and di-leucine motifs in the HIV-1 envelope cytoplasmic domain results
in a loss of Env-mediated fusion and infectivity. Retrovirology 8: 37.
62. Brockman MA, Tanzi GO, Walker BD, Allen TM (2006) Use of a novel GFP
reporter cell line to examine replication capacity of CXCR4- and CCR5-tropic
HIV-1 by flow cytometry. J Virol Methods 131: 134–142.
63. Ostrowski MA, Chun TW, Cheseboro B, Stanley SK, Tremblay M (2006)
Detection assays for HIV proteins. Curr Protoc Immunol Chapter 12: Unit 12
15.
64. Carlson JM, Listgarten J, Pfeifer N, Tan V, Kadie C, et al. (2012) Widespread
impact of HLA restriction on immune control and escape pathways of HIV-1.
J Virol 86: 5230–5243.
65. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies.
Proc Natl Acad Sci U S A 100: 9440–9445.
66. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, et al. (2001) Virologic and
immunologic determinants of heterosexual transmission of human immunode-
ficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 17: 901–910.
67. Saag MS, Holodniy M, Kuritzkes DR, O’Brien WA, Coombs R, et al. (1996)
HIV viral load markers in clinical practice. Nat Med 2: 625–629.
68. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, et al. (1996)
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.
Science 272: 1167–1170.
69. Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, et al. (2006)
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in
untreated HIV infection. JAMA 296: 1498–1506.
70. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, et al. (1990) The
prognostic value of cellular and serologic markers in infection with human
immunodeficiency virus type 1. N Engl J Med 322: 166–172.
71. Crowley S, Rollins N, Shaffer N, Guerma T, Vitoria M, et al. (2010) New WHO
HIV treatment and prevention guidelines. Lancet 375: 874–875.
72. Freed EO, Orenstein JM, Buckler-White AJ, Martin MA (1994) Single amino
acid changes in the human immunodeficiency virus type 1 matrix protein block
virus particle production. J Virol 68: 5311–5320.
73. Spearman P, Horton R, Ratner L, Kuli-Zade I (1997) Membrane binding of
human immunodeficiency virus type 1 matrix protein in vivo supports a
conformational myristyl switch mechanism. J Virol 71: 6582–6592.
74. Ganser-Pornillos BK, von Schwedler UK, Stray KM, Aiken C, Sundquist WI
(2004) Assembly properties of the human immunodeficiency virus type 1 CA
protein. J Virol 78: 2545–2552.
75. Weiss ER, Gottlinger H (2011) The role of cellular factors in promoting HIV
budding. J Mol Biol 410: 525–533.
76. Gottlinger HG, Dorfman T, Sodroski JG, Haseltine WA (1991) Effect of
mutations affecting the p6 gag protein on human immunodeficiency virus
particle release. Proc Natl Acad Sci U S A 88: 3195–3199.
77. von Schwedler UK, Stemmler TL, Klishko VY, Li S, Albertine KH, et al. (1998)
Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral
core assembly. EMBO J 17: 1555–1568.
78. Forshey BM, von Schwedler U, Sundquist WI, Aiken C (2002) Formation of a
human immunodeficiency virus type 1 core of optimal stability is crucial for viral
replication. J Virol 76: 5667–5677.
79. Dorfman T, Mammano F, Haseltine WA, Gottlinger HG (1994) Role of the
matrix protein in the virion association of the human immunodeficiency virus
type 1 envelope glycoprotein. J Virol 68: 1689–1696.
80. Freed EO, Martin MA (1996) Domains of the human immunodeficiency virus
type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into
virions. J Virol 70: 341–351.
81. Krausslich HG, Facke M, Heuser AM, Konvalinka J, Zentgraf H (1995) The
spacer peptide between human immunodeficiency virus capsid and nucleocapsid
proteins is essential for ordered assembly and viral infectivity. J Virol 69: 3407–
3419.
82. Wright ER, Schooler JB, Ding HJ, Kieffer C, Fillmore C, et al. (2007) Electron
cryotomography of immature HIV-1 virions reveals the structure of the CA and
SP1 Gag shells. EMBO J 26: 2218–2226.
83. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, et al. (2003) PA-457:
a potent HIV inhibitor that disrupts core condensation by targeting a late step in
Gag processing. Proc Natl Acad Sci U S A 100: 13555–13560.
84. Lu W, Salzwedel K, Wang D, Chakravarty S, Freed EO, et al. (2011) A single
polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance
to the maturation inhibitor bevirimat. Antimicrob Agents Chemother 55: 3324–
3329.
85. Lazaryan A, Song W, Lobashevsky E, Tang J, Shrestha S, et al. (2011) The
influence of human leukocyte antigen class I alleles and their population
frequencies on human immunodeficiency virus type 1 control among African
Americans. Hum Immunol 72: 312–318.
86. Matthews PC, Adland E, Listgarten J, Leslie A, Mkhwanazi N, et al. (2011)
HLA-A*7401-mediated control of HIV viremia is independent of its linkage
disequilibrium with HLA-B*5703. J Immunol 186: 5675–5686.
87. Fledderman EL, Fujii K, Ghanam RH, Waki K, Prevelige PE, et al. (2010)
Myristate exposure in the human immunodeficiency virus type 1 matrix protein
is modulated by pH. Biochemistry 49: 9551–9562.
88. Zhou W, Parent LJ, Wills JW, Resh MD (1994) Identification of a membrane-
binding domain within the amino-terminal region of human immunodeficiency
virus type 1 Gag protein which interacts with acidic phospholipids. J Virol 68:
2556–2569.
89. Navis M, Matas DE, Rachinger A, Koning FA, van Swieten P, et al. (2008) Molecular
evolution of human immunodeficiency virus type 1 upon transmission between
human leukocyte antigen disparate donor-recipient pairs. PLoS One 3: e2422.
90. Poon A, Chao L (2005) The rate of compensatory mutation in the DNA
bacteriophage phiX174. Genetics 170: 989–999.
91. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, et al. (2003) T cell activation
is associated with lower CD4+ T cell gains in human immunodeficiency virus-
infected patients with sustained viral suppression during antiretroviral therapy.
J Infect Dis 187: 1534–1543.
HIV-1 Replicative Capacity and Early Pathogenesis
PLOS Pathogens | www.plospathogens.org 15 November 2012 | Volume 8 | Issue 11 | e1003041
